유전체 엔지니어링 시장 : 제공 내용, 기술, 제공 방법, 용도, 최종 사용자별 예측(2026-2032년)

The Genome Engineering Market is projected to grow by USD 24.24 billion at a CAGR of 16.17% by 2032.

Genome engineering is moving from a research-intensive discipline into a commercially validated pillar of precision medicine, biomanufacturing, agriculture, and synthetic biology. The field is anchored by CRISPR-Cas systems, base editing, prime editing, zinc finger nucleases, TALENs, viral and non-viral delivery platforms, and increasingly automated design-build-test-learn workflows.

Commercial momentum has accelerated as regulators began approving CRISPR-based therapies. The United Kingdom authorized the first CRISPR-based therapy in November 2023, followed by the United States in December 2023 for sickle cell disease, marking a major milestone for therapeutic genome editing. This validation is expanding strategic interest across cell and gene therapy, oncology, rare disease, infectious disease research, crop trait development, and industrial biotechnology.

Transformative Shifts in the Genome Engineering Landscape

The genome engineering landscape is being reshaped by the convergence of programmable nucleases, high-throughput sequencing, improved delivery systems, and cloud-enabled computational biology. CRISPR-Cas9 remains the most widely adopted platform, while base editing and prime editing are gaining attention because they may enable more precise edits without relying on double-strand DNA breaks.

The market is also shifting from tool adoption toward integrated platforms. Buyers increasingly evaluate end-to-end capabilities, including guide RNA design, off-target analysis, cell engineering, analytical validation, GMP manufacturing readiness, and regulatory documentation. This is raising the competitive importance of quality systems, reproducibility, data integrity, intellectual property strategy, and scalable delivery technologies.

Cumulative Impact of Artificial Intelligence on Genome Engineering

Artificial intelligence is becoming a foundational layer for genome engineering because it can accelerate target discovery, guide RNA selection, protein engineering, and off-target risk prediction. AI models trained on genomic, transcriptomic, proteomic, and clinical datasets are helping researchers prioritize edits and reduce experimental cycles.

A defining proof point is the broad availability of predicted protein structures through resources such as the AlphaFold Protein Structure Database, which expanded structural biology access at unprecedented scale. In genome engineering, similar AI-enabled approaches are improving enzyme discovery, CRISPR variant design, delivery-vector optimization, and cell-line engineering, while also increasing the need for transparent model validation and responsible data governance.

Key Regional Insights Across the Genome Engineering Market

Asia-Pacific is gaining importance through China, Japan, South Korea, India, Singapore, and Australia, where national biotechnology strategies, expanding sequencing capacity, and strong academic pipelines support genome engineering adoption. China has a large clinical research ecosystem for cell and gene therapy, Japan and South Korea emphasize advanced therapeutics and regenerative medicine, India is scaling biotech capacity through national bioeconomy initiatives, and Australia remains active in translational genomics and clinical research.

North America remains a global anchor for genome engineering commercialization, supported by the United States and Canada, deep venture capital networks, leading universities, FDA regulatory pathways, and a mature biopharma ecosystem. Europe is differentiated by strong research infrastructure, Horizon Europe funding, EMA oversight, and national genomics programs, while Latin America is emerging through Brazil and Mexico in agricultural biotechnology, public health genomics, and research partnerships. The Middle East is building genomics capacity through precision medicine programs, and Africa is advancing genomics through infectious disease surveillance, agriculture, and regional research networks supported by pathogen genomics and public health initiatives.

Key Group Insights for Genome Engineering Adoption

ASEAN is becoming more relevant as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines invest in biotechnology, precision medicine, and agricultural innovation. Singapore is the region's strongest translational hub, while broader ASEAN demand is supported by food security priorities, disease surveillance, and expanding life sciences infrastructure.

The GCC is prioritizing genomics as part of healthcare modernization, particularly through national genome programs and precision medicine investments in Saudi Arabia, the United Arab Emirates, and Qatar. The European Union combines strong research funding with rigorous governance for advanced therapies and genetically modified organisms. BRICS nations represent scale, biodiversity, clinical research depth, and manufacturing potential, while the G7 continues to lead in regulatory science, intellectual property, advanced biomanufacturing, and clinical translation. NATO countries add relevance through biosecurity, supply chain resilience, pathogen surveillance, and dual-use technology governance.

Key Country Insights Across Leading Genome Engineering Markets

The United States leads in genome engineering commercialization due to FDA-approved gene-editing therapies, a dense venture ecosystem, major academic medical centers, and advanced CRISPR, cell therapy, and synthetic biology capabilities. Canada is active in stem cell research, genomics, and biomanufacturing, while Mexico is building biotechnology capacity linked to healthcare, agriculture, and North American supply chains. Brazil is a major Latin American hub for agricultural biotechnology, biodiversity research, and biomedical innovation.

In Europe, the United Kingdom has demonstrated regulatory leadership through early authorization of a CRISPR-based therapy, while Germany and France remain central to life sciences R&D, diagnostics, and biomanufacturing. Italy and Spain contribute strong clinical research and translational medicine capabilities, and Russia maintains scientific capacity in genetics and molecular biology despite geopolitical constraints. In Asia-Pacific, China is one of the largest genome engineering research markets, India is scaling biotech and vaccine manufacturing strength, Japan is advanced in regenerative medicine and precision health, Australia is strong in genomics-led clinical research, and South Korea combines biomanufacturing scale with advanced therapeutics investment.

Actionable Recommendations for Genome Engineering Leaders

Industry leaders should prioritize clinically and commercially validated use cases, especially where genome engineering offers measurable advantages over conventional modalities. Strategic focus areas include ex vivo cell therapy, in vivo editing delivery, rare disease programs, oncology applications, functional genomics, engineered cell lines, and climate-resilient crops.

Organizations should strengthen AI-enabled design capabilities, invest in off-target and long-read sequencing validation, secure freedom-to-operate assessments, and build regulatory-ready data packages early. Partnerships with academic centers, contract development and manufacturing organizations, sequencing providers, and cloud bioinformatics platforms can reduce development risk and improve scalability.

Research Methodology

This executive summary is based on a structured secondary research approach using verified public sources, including regulatory agency announcements, peer-reviewed scientific literature, clinical trial registries, patent landscapes, government biotechnology strategies, and recognized genomics and structural biology databases.

Insights were synthesized through market triangulation across technology adoption, regulatory milestones, regional policy signals, funding activity, clinical translation, and application-level demand. The analysis emphasizes data-backed developments and avoids unsupported market sizing where independently verifiable figures are not available.

Conclusion

Genome engineering has entered a new phase defined by regulatory validation, rapid platform innovation, and broader adoption across healthcare, agriculture, and industrial biotechnology. CRISPR-based approvals have shifted the field from scientific promise to therapeutic precedent, while AI and automation are improving speed, accuracy, and scalability.

The next stage of competition will be shaped by delivery performance, safety evidence, manufacturing readiness, data governance, intellectual property strength, and global regulatory alignment. Organizations that combine scientific rigor with scalable platforms and responsible commercialization will be best positioned to lead the genome engineering market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genome Engineering Market, by Offering

• 7.1. Instruments
  • 7.1.1. Electroporation Systems
  • 7.1.2. Microinjection Systems
• 7.2. Reagents & Consumables
  • 7.2.1. Delivery Reagents
  • 7.2.2. Kits & Enzymes
• 7.3. Software
  • 7.3.1. Data Analysis
  • 7.3.2. Design
• 7.4. Services
  • 7.4.1. Screening
  • 7.4.2. Assay Development

8. Genome Engineering Market, by Technology

• 8.1. CRISPR Systems
  • 8.1.1. CRISPR/Cas12
  • 8.1.2. CRISPR/Cas9
• 8.2. Meganucleases
• 8.3. Transcription Control

9. Genome Engineering Market, by Delivery Method

• 9.1. Ex-vivo
• 9.2. In-vivo

10. Genome Engineering Market, by Application

• 10.1. Genetic Engineering
• 10.2. Clinical Therapeutics
• 10.3. Research & Discovery

11. Genome Engineering Market, by End User

• 11.1. Academic & Research Institutes
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical & Biotechnology Companies

12. Genome Engineering Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Genome Engineering Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Genome Engineering Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AgBiome, Inc.
• 16.2. Agilent Technologies, Inc.
• 16.3. BASF SE
• 16.4. Bayer AG
• 16.5. Beam Therapeutics
• 16.6. Bio-Rad Laboratories, Inc.
• 16.7. Charles River Laboratories Inc.
• 16.8. Cibus Inc.
• 16.9. Clinisys, Inc.
• 16.10. Corteva Agriscience
• 16.11. Creative Biogene
• 16.12. CRISPR Therapeutics AG
• 16.13. Danaher Corporation
• 16.14. GenScript Biotech Corporation
• 16.15. Groupe Limagrain Holding
• 16.16. Intellia Therapeutics, Inc.
• 16.17. Lonza Group AG
• 16.18. Merck KGaA
• 16.19. New England Biolabs
• 16.20. QIAGEN N.V.
• 16.21. Revvity Inc.
• 16.22. Synthego Holdings LLC
• 16.23. Takara Bio Inc.
• 16.24. Thermo Fisher Scientific Inc.
• 16.25. Twist Bioscience